D. Western Therapeutics Institute, Inc. Announces Consolidated Earnings Results for the Sis Months Ended June 30, 2020
August 14, 2020 at 02:30 am EDT
Share
D. Western Therapeutics Institute, Inc. announced consolidated earnings results for the sis months ended June 30, 2020. For the period, the company reported net sales of JPY 151 million against JPY 363 million a year ago. Operating loss was JPY 100 million against profit of JPY 127 million a year ago. Net loss was JPY 112.007 million or JPY 3.69 per basic share against profit of JPY 121.141 million or JPY 5.15 per basic share a year ago.
D.Western Therapeutics Institute, Inc. is a Japan-based company engaged in the research and development of new pharmaceuticals. The Company generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Companyâs drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The Company is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.
D. WESTERN THERAPEUTICS INSTITUTE, INC. 
